Gender-specific pharmacology: Implications for therapy

Consultant Pharmacist

Volumn 21, Issue 8, 2006, Pages 620-634

  Martin, Caren McHenry ^a  

^a NONE

Author keywords

Disease prevalence; Elderly; Gender; Pharmacodynamic; Pharmacokinetic; Pharmacotherapy

Indexed keywords

AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHLORPROMAZINE; CIPROFLOXACIN; CLARITHROMYCIN; CYTOCHROME P450 1A; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; DIAZEPAM; DISOPYRAMIDE; ERYTHROMYCIN; GLUCURONOSYLTRANSFERASE; HALOPERIDOL; HORMONE; LIVER ENZYME; METHYLPREDNISOLONE; METHYLTRANSFERASE; MONOAMINE OXIDASE INHIBITOR; NIFEDIPINE; OXIDOREDUCTASE; PROCAINAMIDE; QUINIDINE; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; SOTALOL; THIORIDAZINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VERAPAMIL;

DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG METABOLISM; DRUG RESEARCH; DRUG USE; FEMALE; HISTORY; HUMAN; MALE; MEDICAL RESEARCH; PHARMACEUTICAL CARE; PREVALENCE; QT PROLONGATION; REVIEW; SEX DIFFERENCE; SUSTAINED RELEASE FORMULATION; TORSADE DES POINTES;

EID: 33845296948     PISSN: 08885109     EISSN: None     Source Type: Journal    
DOI: 10.4140/tcp.n.2006.620     Document Type: Review

References (23)

1. U. S. Department of Health and Human Services Health Service, National Institutes of Health. 1999. Agenda for research on women's health for the 21st century: a report of the Task Force on the NIH Women's Health Research.
2. Ensom MH. Gender-based differences and menstrual cycle-related changes in specific diseases: implications for pharmacotherapy. Pharmacotherapy 2000;20:523-39.
3. Roquer J, Campello AR, Gomis Sex Differences in First-Ever Acute Stroke. Stroke 2003;34:1581-5.
4. Simon T, Mary-Krause M, Funck-Bretano C et al. Gender differences in the prognosis of congestive heart failure: results from the Cardiac Insufficiency Bisoprolol study (CIBIS II). Circulation 2001;103:375.
5. Chapman KR, Tashkin DP, Pye DJ et al. Gender differences in the management and experience of chronic obstructive pulmonary disease. Respir Med 2004;98:1207-13.
6. Tashkin DP, Altose MD, Connett JE et al. Methacholine reactivity predicts changes in lung function over time in smokers with early chronic obstructive pulmonary disease. The Lung Health Study research group. Am J Respir Crit Care Med 1996;153:1802-11.
7. Mendelsohn ME, Karas RH. Medical biology: gender differences in cardiovascular disease. Science 2005;308:1583.
8. Gandhi M, Aweeka F, Greenblatt RM et al. Gender differences in pharmacokinetics and pharmacodynamics. Annu Rev Pharmacol Toxicol 2004;44:499-523.
9. Krecic-Shepard ME, Barnas CR, Slimko J et al. Faster clearance of sustained release verapamil in men versus women: continuing observations of gender-specific differences after oral administration of verapamil. Clin Pharmacol Ther 2000;68:286-92.
10. Overholser BR, Kays MB, Forrest A et al. Gender-related differences in the pharmacokinetics of oral ciprofloxacin. J Clin Pharmacol 2004;44:1012-22.
11. Och HR, Grerenblatt DJ, Divoll M et al. Diazepam kinetics in relation to age and gender. Pharmacology 1981;23:24-30.
12. Schwartz JB. The influence of gender on pharmacokinetics. Clin Pharmacokinet 2003;42:107-21.
13. Hunt CM, Westerkam WR, Stave GM. Effect of age and gender on the activity of human hepatic CYP3A. Biochem Pharmacol 1992;44:275-83.
14. Austin KL, Mather LE, Philpot CR et al. Intersubject and dose-related variability after intravenous administration of erythromycin. Br J Clin Pharmacol 1980;10:273-9.
15. Prior TI, Baker GB. Interactions between the cytochrome P450 system and the second-generation antipsychotics. J Psychiatry Neurosci 2003;28:99-112.
16. Overholser, BR, Kays MB, Lagvankar S et al. Pharmacokinetics of intravenously administered levofloxacin in men and women. Pharmacotherapy 2005;25:1310-8.
17. Rademaker M. Do women have more adverse drug reactions? Am J Clin Dermatol 2001;2:349-51.
18. Benton RE, Sale M, Flockhart DA et al. Greater quinidine induced QTc interval prolongation in women. Clin Pharmacol Ther 2000;67:413-8.
19. Crouch MA, Limon L, Cassano AT. Clinical relevance and management of drug-related QT interval prolongation. Pharmacotherapy 2003;23:881-908.
20. Luzier AB, Killian A, Wilton JH et al. Gender-related effects of metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers. Clin Pharmacol Ther 1999;66:594-601.
21. Gear RW, Miaskowski C, Gordon NC et al. The kappa opioid nalbuphine produces gender and dose dependent analgesia and antianalgesia in patients with postoperative pain. Pain 1999;83:339-45.
22. Slavkin HC. Distinguishing Mars from Venus: emergence of gender biology in health and disease. JADA 1998;129:357-61.
23. American Heart Association. Heart disease and stroke statistics - 2006 update. Dallas, TX: American Heart Association; 2006.